Article citationsMore>>

Veerman, A.J., Kamps, W.A., Van den Berg, H., Van den Berg, E., Bokkerink, J.P., Bruin, M.C., Van den Heuvel-Eibrink, M.M., Korbijn, C.M., Korthof, E.T., Van der Pal, K., Stijnen, T., Van Weel Sipman, M.H., Van Weerden, J.F., Van Wering, E.R.A. and Van der Does-Van den Berg, G. (2009) Dutch Childhood Oncology, Dexamethasone-Based Therapy for Childhood Acute Lymphoblastic Leukaemia: Results of the Prospective Dutch Childhood Oncology Group (DCOG) Protocol ALL-9 (1997-2004). Lancet Oncology, 10, 957-966.
https://doi.org/10.1016/S1470-2045(09)70228-1

has been cited by the following article:

• TITLE: Dexamethasone versus Prednisone in Childhood Acute Lymphoblastic Leukemia Treatment: Results of the Indonesian Randomized Trial

  AUTHORS: Pudjo H. Widjajanto, Eddy Supriyadi, Ignatius Purwanto, Jacqueline Cloos, Peter M. vdVen, Sutaryo, Anjo JP. Veerman

  KEYWORDS: Dexamethasone versus Prednisone, Childhood ALL, Indonesia

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.8, August 3, 2017

  ABSTRACT: Background: Randomized trials report that, compared to prednisone, dexamethasone has reduced CNS relapse and improved event-free survival (EFS), despite a trend toward a higher risk for induction death. Because toxic death is a specific problem in the Indonesian setting, this study compares the outcome of dexamethasone versus prednisone. Methods: In the period 2006 - 2011, 196 patients with childhood acute lymphoblastic leukemia (ALL) treated on the Indonesia-ALL-2006 protocol [first standard risk (SR) and later high risk (HR) patients] were randomized to receive dexamethasone or prednisone as steroid. Patients in the dexamethasone arm (n = 102: 68 SR, 34 HR) received dexamethasone 4 mg/m2/day (SR) or 6 mg/m2/day (HR), while the prednisone arm (n = 94: 66 SR, 28 HR) received prednisone 40 mg/m2/day (SR and HR). Results: Patients in the dexamethasone arm showed no significant difference compared to the prednisone arm in abandonment rate (24.5% vs. 25.5%, P = 0.91), death rate (17.7% vs. 14.9%, P = 0.54), or leukemic events (13.7 vs. 11.7%, P = 0.59). After stratification for risk group, a trend towards a higher death rate was found in the dexamethasone arm of SR patients (16.2 vs. 6.1%, P = 0.06). The 3-year survival for EFS in SR and HR patients for dexamethasone versus prednisone was 31.5% ± 6.6% vs. 41.5% ± 5.9% (P = 0.51), for leukemia-free survival (LFS) it was 63.7% ± 9.3% vs. 74.5% ± 7.6% (P = 0.47), and for overall survival (OS) it was 49.5% ± 7.7% vs. 69.3% ± 6.1% (P = 0.09). Conclusions: In our setting, a trend toward higher induction deaths was observed in the dexamethasone arm of SR patients and the 3-year EFS; LFS and OS rates were lower in the dexamethasone group; however, these differences were not significant.